FindTrial
Sign In

Clinical Efficacy and Safety Analysis of Janus Kinase Inhibitor in the Treatment of Moderate to Severe Atopic Dermatitis

Clinical Efficacy and Safety Analysis of Janus Kinase Inhibitor in the Treatment of Moderate to Severe Atopic Dermatitis

Status
Unknown
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071142
Enrollment
Unknown
Registered
2023-05-06
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Interventions

Abrocitinib group:None
Tofacitinib group:None
Upadacitinib group:None

Sponsors

Jining First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18 to 65 years old; 2. Diagnose AD according to Williams AD diagnostic criteria; 3. >=10% BSA, EASI >=16; 4. Voluntary signing of informed consen.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of thrombotic events (including deep vein thrombosis, pulmonary embolism, and cerebrovascular diseases), and patients with other known internal conditions that may easily lead to hypercoagulability; 2. Pregnant or lactating patients; 3. Those who are contraindicated by Jak inhibitors.

Design outcomes

Primary

MeasureTime frame
Investigator's Global Assessment (IGA) score;Itching Visual Analogue Scale (VAS) score;Eczema Area and Severity Index (EASI) score;Dermatology Life Quality Index (DLQI);Patient-Oriented Eczema Measure (POEM);Body Surface Area (BSA);Atopic Dermatitis Control Tool (ADCT);Scoring AD (SCORAD);—

Countries

China

Contacts

Public ContactDongmei Shi

Jining First People's Hospital

shidongmei28@163.com+86 18678769757

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026